靶向血小板衍生生长因子受体-β的89Zr标记Fibrobody®用于肝纤维化的临床前靶向研究
本研究评估双价VHH构建体Fibrobody® SP02SP26-ABD靶向血小板衍生生长因子受体-β(PDGFRβ)用于肝纤维化诊疗的潜力。该分子对人、小鼠和大鼠PDGFRβ具有相似的纳摩尔亲和力,在PDGFRβ表达细胞中观察到细胞摄取和auristatinF偶联物的亚纳摩尔细胞毒性。在三种小鼠肝纤维化模型中,[89Zr]Zr-SP02SP26-ABD的PET-CT显像和生物分布显示纤维化肝脏中PDGFRβ特异性摄取增高。
要点
- SP02SP26-ABD对人、小鼠和大鼠PDGFRβ具有相似的纳摩尔亲和力。
- 在三种小鼠肝纤维化模型中,[89Zr]Zr-SP02SP26-ABD在纤维化肝脏中显示PDGFRβ特异性摄取增高。
- DDC模型中肝摄取随纤维化进展从第1周12.15 ± 0.45%ID/g升至第4周20.93 ± 4.35%ID/g,健康小鼠为7.56 ± 0.85%ID/g。
核心结论
- 抗PDGFRβ Fibrobody® SP02SP26-ABD对肝纤维化中活化的肌成纤维细胞显示选择性且高程度的靶向,可作为诊断和治疗用途的载体。
研究设计与样本
- 临床前研究,评估SP02SP26-ABD的特异性、跨物种结合和细胞摄取,并在人肝样本和3种小鼠肝纤维化模型(DDC、CCl4、CDA-HFD)中验证PDGFRβ作为活动性纤维化标志物。
- 将DFO*-SP02SP26-ABD用89Zr标记后,在健康小鼠和肝纤维化小鼠中通过PET-CT显像、离体生物分布和放射自显影评估体内靶向能力。
主要发现
- SP02SP26-ABD对人、小鼠和大鼠PDGFRβ显示相似的纳摩尔亲和力。
- 在PDGFRβ表达细胞系中观察到细胞摄取以及auristatinF偶联的SP02SP26-ABD的亚纳摩尔细胞毒性效力。
- 小鼠和人纤维化肝脏的免疫组化证实PDGFRβ与活动性纤维化标志物共定位。
- 在全部三种肝纤维化模型中,[89Zr]Zr-SP02SP26-ABD的PET-CT显像和生物分布分析显示纤维化肝脏中PDGFRβ特异性摄取增高。
- DDC模型中纤维化形成第1、2、3、4周后肝摄取分别为12.15 ± 0.45、15.07 ± 0.90、20.23 ± 1.34和20.93 ± 4.35%ID/g,健康小鼠为7.56 ± 0.85%ID/g。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hepatic fibrosis develops as a response to chronic liver injury, resulting in the formation of fibrous scars. This process is initiated and driven by collagen-producing activated myofibroblasts which reportedly express high levels of platelet derived growth factor receptor-β (PDGFRβ). We therefore regard PDGFRβ as an anchor for diagnosis and therapy. The Fibrobody® SP02SP26-ABD is a biparatopic VHH-construct targeting PDGFRβ. Here, we explore its potential as a theranostic vector for liver fibrosis. METHODS: Specificity, cross-species binding, and cellular uptake of SP02SP26-ABD was assessed using human, mouse and rat PDGFRβ ectodomains and PDGFRβ-expressing cells. Cellular uptake by PDGFRβ-expressing cells was also evaluated by equipping the Fibrobody® with auristatinF and reading out in vitro cytotoxicity. The validity of PDGFRβ as a marker for active fibrosis was confirmed in human liver samples and 3 mouse models of liver fibrosis (DDC, CCl4, CDA-HFD) through immunohistochemistry and RT-PCR. After radiolabeling of DFO*-SP02SP26-ABD with 89Zr, its in vivo targeting ability was assessed in healthy mice and mice with liver fibrosis by PET-CT imaging, ex vivo biodistribution and autoradiography. RESULTS: SP02SP26-ABD shows similar nanomolar affinity for human, mouse and rat PDGFRβ. Cellular uptake and hence subnanomolar cytotoxic potency of auristatinF-conjugated SP02SP26-ABD was observed in PDGFRβ-expressing cell lines. Immunohistochemistry of mouse and human fibrotic livers confirmed co-localization of PDGFRβ with markers of active fibrosis. In all three liver fibrosis models, PET-CT imaging and biodistribution analysis of [89Zr]Zr-SP02SP26-ABD revealed increased PDGFRβ-specific uptake in fibrotic livers. In the DDC model, liver uptake was 12.15 ± 0.45, 15.07 ± 0.90, 20.23 ± 1.34, and 20.93 ± 4.35%ID/g after 1,2,3 and 4 weeks of fibrogenesis, respectively, compared to 7.56 ± 0.85%ID/g in healthy mice. Autoradiography revealed preferential uptake in the fibrotic (PDGFRβ-expressing) periportal areas. CONCLUSION: The anti-PDGFRβ Fibrobody® SP02SP26-ABD shows selective and high-degree targeting of activated myofibroblasts in liver fibrosis, and qualifies as a vector for diagnostic and therapeutic purposes.
引用
- Muns JA, Schooten E, van Dasselaar RDJ, et al. Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β. Eur J Nucl Med Mol Imaging. 2024. PMID: 38888612. doi:10.1007/s00259-024-06785-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。